Company Overview and News

 
UPDATE 1-Global investors pile into China stocks ahead of MSCI index entry

2018-04-27 reuters
SHANGHAI (Reuters) - Overseas investors are pumping billions of dollars into Chinese stocks and the country’s asset managers are rushing to launch index-tracking funds in a fervent build-up to China’s inclusion in MSCI’s widely tracked equity benchmarks.

 
Global investors pile into China stocks ahead of MSCI index entry

2018-04-27 reuters
SHANGHAI, April 27 (Reuters) - Overseas investors are pumping billions of dollars into Chinese stocks and the country’s asset managers are rushing to launch index-tracking funds in a fervent build-up to China’s inclusion in MSCI’s widely tracked equity benchmarks.

2
Fosun Lives Twice, But an MGM Raid Could Change That - Bloomberg

2018-04-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

1
Chinese conglomerate Fosun to invest 100b yuan in AI, biotech and fintech over next decade

2018-03-28 scmp
Chinese conglomerate Fosun International is looking to invest in areas such as biotechnology, financial technology and artificial intelligence, according to its chairman, Guo Guangchang. This investment will amount to 20 billion yuan (US$3.2 billion) over the next three years, and 100 billion yuan over the next decade, according to Wang Qunbin, the company’s chief executive.

 
China Wants Its Tech Firms Back. Are CDRs the Answer? - Bloomberg

2018-03-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Exclusive: China Resources Beer in talks to acquire Heineken's China business - sources

2018-03-09 in.reuters
HONG KONG (Reuters) - China Resources Beer (Holdings) Co Ltd is in talks to acquire Heineken NV’s China business in a deal that could be worth more than $1 billion, as the country’s largest brewer seeks new growth from premium brands, five people close to the discussions said.

 
China Resources Beer in talks to acquire Heineken's China business: Sources

2018-03-08 channelnewsasia
China Resources Beer (Holdings) Co Ltd is in talks to acquire Heineken NV’s China business in a deal that could be worth more than US$1 billion, as the country's largest brewer seeks new growth from premium brands, five people close to the discussions said.

 
Exclusive: China Resources Beer in talks to acquire Heineken's China business - sources - Channel NewsAsia

2018-03-08 channelnewsasia
China Resources Beer (Holdings) Co Ltd is in talks to acquire Heineken NV’s China business in a deal that could be worth more than US$1 billion, as the country's largest brewer seeks new growth from premium brands, five people close to the discussions said.

 
Exclusive: China Resources Beer in talks to acquire Heineken's China business - sources

2018-03-08 reuters
HONG KONG (Reuters) - China Resources Beer (Holdings) Co Ltd is in talks to acquire Heineken NV’s China business in a deal that could be worth more than $1 billion, as the country’s largest brewer seeks new growth from premium brands, five people close to the discussions said.

 
China Resources Beer in talks to acquire Heineken's China business - sources

2018-03-08 in.reuters
HONG KONG (Reuters) - China Resources Beer (Holdings) Co Ltd is in talks to acquire Heineken NV’s China business in a deal that could be worth more than $1 billion, as the country’s largest brewer seeks new growth from premium brands, five people close to the discussions said.

 
China Stocks So Hot a Cold Beer Can't Douse - Bloomberg

2018-01-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
China’s top beer makers lift prices in tandem for the first time in a decade

2018-01-08 scmp
The moves come as the country’s brewers suffer from low profit margins because of rising labour costs, higher material prices after China’s new environmental policy, as well as increased competition from imported brands

1
China, Hong Kong shares keep climbing; developers lend support

2018-01-05 thehindubusinessline
China and Hong Kong stocks extended their New Year rally on Friday, underpinned by robust gains in real estate firms. At 04:02 GMT, the Shanghai Composite index was up 7.95 points or 0.23 per cent at 3,393.66. China's blue-chip CSI300 index was up 0.24 per cent, with its financial sector sub-index higher by 0.61 per cent, the consumer staples sector down 0.4 per cent , the real estate index up 4.77 per cent and healthcare sub-index up 0.

 
Hong Kong stocks extend gains to a 9th session in winning start to 2018

2018-01-05 scmp
The Hang Seng Index posts its best weekly gain since October, while Shanghai shares record their biggest weekly jump in more than a year

 
HNA. Fosun Need to Jettison More Than Real Estate - Bloomberg

2017-12-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...